CN100577666C - 作为m4毒蕈碱性受体的变构增效剂的噻吩并吡啶类 - Google Patents

作为m4毒蕈碱性受体的变构增效剂的噻吩并吡啶类 Download PDF

Info

Publication number
CN100577666C
CN100577666C CN200580036624A CN200580036624A CN100577666C CN 100577666 C CN100577666 C CN 100577666C CN 200580036624 A CN200580036624 A CN 200580036624A CN 200580036624 A CN200580036624 A CN 200580036624A CN 100577666 C CN100577666 C CN 100577666C
Authority
CN
China
Prior art keywords
compound
methyl
chloro
amino
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200580036624A
Other languages
English (en)
Chinese (zh)
Other versions
CN101048413A (zh
Inventor
A·鲁比奥埃斯特班
D·W·希利亚德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101048413A publication Critical patent/CN101048413A/zh
Application granted granted Critical
Publication of CN100577666C publication Critical patent/CN100577666C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
CN200580036624A 2004-10-25 2005-10-18 作为m4毒蕈碱性受体的变构增效剂的噻吩并吡啶类 Expired - Fee Related CN100577666C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62178504P 2004-10-25 2004-10-25
US60/621,785 2004-10-25

Publications (2)

Publication Number Publication Date
CN101048413A CN101048413A (zh) 2007-10-03
CN100577666C true CN100577666C (zh) 2010-01-06

Family

ID=36021809

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200580036624A Expired - Fee Related CN100577666C (zh) 2004-10-25 2005-10-18 作为m4毒蕈碱性受体的变构增效剂的噻吩并吡啶类

Country Status (16)

Country Link
US (1) US8071776B2 (enExample)
EP (1) EP1807434B1 (enExample)
JP (1) JP4945453B2 (enExample)
CN (1) CN100577666C (enExample)
AT (1) ATE478876T1 (enExample)
AU (1) AU2005299957B2 (enExample)
BR (1) BRPI0517438A (enExample)
CA (1) CA2583550C (enExample)
CY (1) CY1111477T1 (enExample)
DE (1) DE602005023197D1 (enExample)
DK (1) DK1807434T3 (enExample)
ES (1) ES2349416T3 (enExample)
MX (1) MX2007004794A (enExample)
PL (1) PL1807434T3 (enExample)
PT (1) PT1807434E (enExample)
WO (1) WO2006047124A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126856A1 (en) * 2012-02-23 2013-08-29 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2014035829A1 (en) * 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
US9908893B2 (en) 2013-06-11 2018-03-06 Latvian Institute Of Organic Synthesis Thieno [2,3-b] pyridines as multidrug resistance modulators
EP3036233A1 (en) 2013-08-23 2016-06-29 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
ES2789756T3 (es) 2015-12-23 2020-10-26 Merck Sharp & Dohme Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
KR102474326B1 (ko) 2016-06-22 2022-12-05 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제
SG11201811712QA (en) 2016-07-01 2019-01-30 Pfizer 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
US11008335B2 (en) 2016-11-07 2021-05-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
EP3558309B1 (en) 2016-11-07 2023-07-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
ES2892956T3 (es) 2016-11-07 2022-02-07 Univ Vanderbilt Moduladores alostéricos positivos del receptor muscarínico de acetilcolina M4
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
FI3642202T3 (fi) 2017-06-22 2023-03-01 Dihydro-pyrrolo-pyridiinijohdannaisia
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
CN111406058A (zh) 2017-12-05 2020-07-10 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
WO2025201078A1 (zh) * 2024-03-25 2025-10-02 四川科伦药物研究院有限公司 化合物、包含其的药物组合物及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870085A (en) * 1984-08-17 1989-09-26 Bayer Aktiengesellschaft Tryptamine derivatives active on central nervous system
CN1166169A (zh) * 1994-07-27 1997-11-26 三共株式会社 用作毒蕈碱性受体别构效应物的杂环化合物
WO2002076950A2 (en) * 2001-03-21 2002-10-03 Allergan, Inc. Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors
CN1439002A (zh) * 2000-04-28 2003-08-27 阿卡蒂亚药品公司 毒蕈碱性激动剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924962D0 (en) * 1999-10-21 1999-12-22 Mrc Collaborative Centre Allosteric sites on muscarinic receptors
MXPA04007083A (es) * 2002-02-20 2004-10-29 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
US6974870B2 (en) * 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870085A (en) * 1984-08-17 1989-09-26 Bayer Aktiengesellschaft Tryptamine derivatives active on central nervous system
CN1166169A (zh) * 1994-07-27 1997-11-26 三共株式会社 用作毒蕈碱性受体别构效应物的杂环化合物
CN1439002A (zh) * 2000-04-28 2003-08-27 阿卡蒂亚药品公司 毒蕈碱性激动剂
WO2002076950A2 (en) * 2001-03-21 2002-10-03 Allergan, Inc. Imidiazole derivatives and their use as agonists selective at alpha 2b or 2b/2c adrenergic receptors

Also Published As

Publication number Publication date
DE602005023197D1 (de) 2010-10-07
AU2005299957B2 (en) 2011-04-21
JP2008517913A (ja) 2008-05-29
CN101048413A (zh) 2007-10-03
AU2005299957A1 (en) 2006-05-04
DK1807434T3 (da) 2010-11-22
MX2007004794A (es) 2007-07-09
US8071776B2 (en) 2011-12-06
CY1111477T1 (el) 2015-08-05
CA2583550A1 (en) 2006-05-04
PT1807434E (pt) 2010-09-22
EP1807434A1 (en) 2007-07-18
JP4945453B2 (ja) 2012-06-06
WO2006047124A1 (en) 2006-05-04
PL1807434T3 (pl) 2011-02-28
CA2583550C (en) 2013-05-14
ES2349416T3 (es) 2011-01-03
US20090105244A1 (en) 2009-04-23
EP1807434B1 (en) 2010-08-25
ATE478876T1 (de) 2010-09-15
BRPI0517438A (pt) 2008-10-07

Similar Documents

Publication Publication Date Title
CN100577666C (zh) 作为m4毒蕈碱性受体的变构增效剂的噻吩并吡啶类
KR102218621B1 (ko) 선택적 NK-3 수용체 길항제로서의 신규한 N-아실-(3-치환)-(8-치환)-5,6-디히드로-[1,2,4]트리아졸로[4,3-a]피라진, 약학적 조성물, NK-3 수용체-매개 질환에 사용하기 위한 방법
US6586421B2 (en) Substituted azepino[4,5b]indoline derivatives
CN115087440A (zh) Trpml调节剂
WO2024046253A1 (zh) 一种钠通道调节剂及其应用
US20020147341A1 (en) Isomeric fused pyrrolocarbazoles and isoindolones
HUP0104280A2 (hu) Dopamin D3 receptorok modulátoraiként felhasználható tetrahidrobenzazepin-származékok, eljárás az előállításukra, a vegyületeket tartalmazó gyógyszerkészítmények
EP1869052A1 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
NZ547164A (en) Derivatives of n-[phenyl(piperidine-2-yl)methyl]benzamide, preparation and therapeutic use thereof
PT2441753E (pt) Composto tetracíclico
CN111925379B (zh) 含氮杂芳基取代的嘧啶二酮类化合物及其用途
US11028097B2 (en) Thienopyrimidine compounds
SI9300438A (en) Indole and indoline derivates, process for their preparation and use thereof in the treatment
NZ545917A (en) Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
US20220281879A1 (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
US7456192B2 (en) 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof
JP2005526816A (ja) 抗ヒスタミン薬および抗アレルギー薬としてのアザインドリルピペリジン誘導体
CN103492392A (zh) 噻吩并[2,3-d]嘧啶衍生物及其用于治疗心律失常的用途
CZ290678B6 (cs) 3-Substituované 3,4,5,7-tetrahydropyrrolo[3´,4´: 4,5]thieno[2,3-d]pyrimidinové deriváty, způsob jejich přípravy a použití
NZ540768A (en) Benzamide derivatives as oxytocin agonists and vasopressin antagonists
CN112041319B (zh) 三唑、咪唑和吡咯稠合的哌嗪衍生物及其作为mGlu5受体的调节剂的应用
CN111909168B (zh) 含氮杂环基取代的嘧啶二酮类化合物及其用途
CN112047957B (zh) 取代的嘧啶二酮类化合物及其用途
US4931436A (en) Condensed diazepinones, processes for preparing them and pharmaceutical compositions containing these compounds
JPWO2004080965A1 (ja) ニューロペプチドｆｆ受容体拮抗剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100106

Termination date: 20181018